ANGO

SEC source: 0001140361-23-036320 · form4.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,005

F2 · shares: The exempt disposition of 1,404 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036320 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,900 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036318 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-036318 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,205

F2 · shares: The exempt disposition of 3,159 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036318 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 8,769 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044837 · form4.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,782 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044837 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,951

F2 · shares: The exempt disposition of 2,716 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044837 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 7,539 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044830 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108,871 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044830 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 564,446

F2 · shares: The exempt disposition of 34,296 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044830 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 69,676 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044840 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044840 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,974

F2 · shares: The exempt disposition of 6,975 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044840 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,949

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 19,354 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044839 · form4.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044839 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,462

F2 · shares: The exempt disposition of 3,477 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044839 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 9,650 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044835 · form4.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 13,453 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 8,610 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 13,453 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 8,610 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 13,453 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 8,610 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044835 · form4.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,016

F2 · shares: The exempt disposition of 3,103 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044835 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 8,610 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-24-033635 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,693

Underlying: Common Stock · 207,693 shares

Expires 2034-07-17

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-23-035084 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

F2 · shares: The exempt disposition of 351 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035086 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,239

F2 · shares: The exempt disposition of 2,262 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035087 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,288

F2 · shares: The exempt disposition of 376 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035085 · form4.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,879

F2 · shares: The exempt disposition of 279 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035083 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,197

F2 · shares: The exempt disposition of 313 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035084 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,479

F1 · shares: The exempt disposition of 517 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035086 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 445,501

F1 · shares: The exempt disposition of 4,906 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035087 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,664

F1 · shares: The exempt disposition of 1,362 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035085 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,158

F1 · shares: The exempt disposition of 596 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035083 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,510

F1 · shares: The exempt disposition of 679 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-028006 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,954

F1 · shares: The exempt disposition of 1,400 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on June 1, 2021.

SEC source: 0001567619-23-002005 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,026

F1 · shares: The exempt disposition of 555 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 3, 2020.

SEC source: 0001567619-23-002003 · doc1.xml · nonDerivative · entry 1

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,730

F1 · shares: The exempt disposition of 1,137 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 1, 2021.

SEC source: 0001567619-23-001649 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,189

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.94 to $12.97, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-018449 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,581

SEC source: 0001567619-22-018410 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,407

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.93 to $15.02, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-014709 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,822

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.43 to $22.46, inclusive. The reporting person has provided to AngioDynamics, Inc. (the "Company"), and undertakes to provide to any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-014352 · doc1.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,777

F1 · shares: The acquisition of 7,060 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,060 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/20/2023.

SEC source: 0001567619-22-014371 · doc1.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,312

Underlying: Common Stock · 10,312 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014371 · doc1.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,803

Underlying: Common Stock · 8,803 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014371 · doc1.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,354

F1 · shares: The acquisition of 4,402 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,402 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014365 · doc1.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,680

Underlying: Common Stock · 8,680 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014365 · doc1.xml · derivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,410

Underlying: Common Stock · 7,410 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014365 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,996

F1 · shares: The acquisition of 3,705 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,705 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014379 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,530

Underlying: Common Stock · 77,530 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014379 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,187

Underlying: Common Stock · 66,187 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014379 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,407

F1 · shares: The acquisition of 33,094 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 33,094 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014350 · doc1.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,461

F1 · shares: The acquisition of 7,060 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,060 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/20/2023.

SEC source: 0001567619-22-014355 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,978

F1 · shares: The acquisition of 7,060 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,060 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/20/2023.